1. Home
  2. WFG vs CRSP Comparison

WFG vs CRSP Comparison

Compare WFG & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo West Fraser Timber Co. Ltd.

WFG

West Fraser Timber Co. Ltd.

HOLD

Current Price

$69.47

Market Cap

5.0B

Sector

N/A

ML Signal

HOLD

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$59.44

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WFG
CRSP
Founded
1955
2013
Country
Canada
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
5.8B
IPO Year
2007
2016

Fundamental Metrics

Financial Performance
Metric
WFG
CRSP
Price
$69.47
$59.44
Analyst Decision
Strong Buy
Buy
Analyst Count
2
17
Target Price
$89.50
$70.29
AVG Volume (30 Days)
206.5K
1.4M
Earning Date
04-29-2026
05-11-2026
Dividend Yield
2.03%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$289,590,000.00
Revenue This Year
$5.05
$807.72
Revenue Next Year
$10.26
$172.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
9169.85
52 Week Low
$57.34
$44.12
52 Week High
$76.99
$78.48

Technical Indicators

Market Signals
Indicator
WFG
CRSP
Relative Strength Index (RSI) 52.05 61.52
Support Level $63.47 $50.45
Resistance Level $72.66 $59.61
Average True Range (ATR) 2.18 2.51
MACD -0.15 0.62
Stochastic Oscillator 46.93 72.57

Price Performance

Historical Comparison
WFG
CRSP

About WFG West Fraser Timber Co. Ltd.

West Fraser Timber is a softwood lumber company that also produces wood panels and pulp products. The company produces its wood products globally, with lumber mills in British Columbia, Alberta, Europe, and the Southeastern United States. Following its acquisition of Norbord in 2021, West Fraser is one of the largest oriented strand board producers in the world.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: